SoluPro™, our all-in-one protein expression platform, produces complex proteins ranging from full-length antibodies to insulin using the simplest, best studied, and least expensive organism, E. coli.
AbSci Advantages
Next-generation E. coli chassis, SoluPro™ produces soluble, disulfide bonded, active protein without refolding
“First-of-its-kind” workflow provides partners a high-titer cell line in 12 weeks that produces high-quality product
Rapid cell line development and elimination of viral clearance allow for gene to GMP drug substance in 6-9 months
Up to 75% reduction in drug substance costs due to high titers and reduced number of production runs
Ultra-High Yield Streamlined Protein Production
OUR TECHNOLOGY
Two key innovations form the foundation of our SoluPro™ protein expression platform: a carefully engineered semi-oxidizing cytoplasm and a dual inducible promoter system that enables precision control over protein production rates. AbSci’s unprecedented approach and proprietary understanding of protein folding enables SoluPure a chromatography-free purification method that removes downstream processing bottlenecks.
This scalable downstream purification technique utilizes existing standard to remove host-cell proteins and eliminate downstream chromatography steps. Together, SoluPure™ and SoluPro™ introduce numerous efficiencies throughout biologic discovery and manufacturing by providing rapid access to therapeutic candidates, simplifying downstream purification, and achieving fermentation titers that can be measured in tens of grams per liter.
Traditionally, protein expression in E. coli is achieved either through cytoplasmic production as inclusion bodies or through secretion into the periplasmic space. SoluPro™ expresses soluble, disulfide linked proteins through production in a semi-oxidized cytoplasm.
AbSci takes advantage of the simplicity of E. coli to assemble and screen large pools of genetic diversity in parallel. Using high-throughput assays and workflows, the ideal production strain can be identified in 3 months or less. Rapid optimization of a high-titer producing strains enables pharmaceutical and biotech partners to go from gene to GMP drug substance in less than 9 months and eliminates the need for viral clearance, which results in dramatic time savings compared to CHO.
At scale, SoluPro™ creates breakthrough efficiencies in biomanufacturing, reducing the number of production campaigns or scale of bioreactor required to produce sufficient drug substance. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.
AbSci’s high throughput workflow generates cell lines that produce folded, active protein product in as little as 3 months.
AbSci’s high throughput workflow generates cell lines that produce folded, active protein product in as little as 3 months.
PARTNERSHIPS
Molecules
Partners
PARTNERSHIPS
Absci collaborates with leading pharmaceutical companies to enable step-changes in productivity to their bio-pharmaceutical R&D and manufacturing.
AbSci is supported by a syndicate of experienced investors:
“People in the industry have been talking about folding protein in E. coli for years. Before it was just theoretically possible, but the SoluPro™ Platform now makes it technically possible to fold full-length antibodies and proteins in E. coli.”
Fred Larimore, PhD, Former Research Fellow at Eli Lilly
ABOUT US
We are a fearless, intellectually energetic team of scientists continually defining the future of drug discovery and manufacturing for the biopharmaceutical industry.
AbSci scientists are iconoclasts, defying established industry practices, resolute in a shared conviction that the status quo for biomanufacturing is obsolete. We attract passionate, imaginative and accomplished scientists who are risk takers, keen to experiment, collaborate and create extraordinary drug discovery and manufacturing tools to disrupt and transform how life-changing biologics are made.
Our Scientific Advisory Board and Board of Directors are comprised of world-class scientists who bring decades of experience leading and igniting the biotech industry in all facets of drug discovery and biomanufacturing.
Zach Jonasson, Ph.D.
Chairman, Managing Partner PVP
V. Bryan Lawlis, Ph.D.
Independent Consultant
Sean McClain
Founder & CEO
Dan Gold, Ph.D.
VP Process Sciences, BioMarin
Gustavo Mahler, Ph.D.
CEO, AGC Biologics
Sean McClain
Founder & CEO
Lawrence McClure, Ph.D., J.D.
VP, Intellectual Property and Licensing
Chris Ulum
VP, Alliance Management & Operations
Shelley Klassen, CPA, CMA
Chief Financial Officer
Penelope
Chief Morale Officer
Martina Molsbergen
VP, Business Development
Johan Kers, PhD
VP, Research
V. Bryan Lawlis, Ph.D.
Chairman, Independent Consultant
Bill Bennett, Ph.D.
Principal, Bioscope Associates
Dan Gold, Ph.D.
VP Process Sciences, BioMarin
Fred Larimore, Ph.D.
Principal, Sierra Vista Biotech
Alan Herman, Ph.D.
CSO, Coherus
Andrew J.S. Jones, D. Phil.
Independent Consultant
“AbSci reminds me of Genentech in the early 80’s, they’ve taken on some really hard problems to explain and there’s no fear around solving these key industry issues.”
V. Bryan Lawlis, PhD, Former VP of Process Science at Genentech
CAREERS
Join the Team | Change an Industry
At AbSci, we defy established protein expression conventions and continually invent new technologies and approaches which introduce efficiencies and cost savings to the biotech industry. We are looking for original thinkers, accomplished and energetic scientists who have the imagination to join us and re-define what’s possible.
NEWS / UPDATES / PRESS
Absci Vancouver